Attached files

file filename
EX-10.1 - EX-10.1 - Aspira Women's Health Inc.vrml-20180627xex10_1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

   


Form 8-K

   


CURRENT REPORT Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2018

   


Vermillion, Inc.

(Exact Name of Registrant as Specified in Charter)

   




   



 

 

Delaware

001-34810

33-0595156

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)





 

 



        12117 Bee Caves Road Building Three, Suite 100, Austin, TX   78738

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:  (512) 519-0400

   


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

   



 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



   

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)





 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))





 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).



Emerging growth company


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 




 


 

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)

As described in Item 5.07 below, at the Vermillion, Inc. (the “Company”) 2018 annual meeting of stockholders held on June 21, 2018 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “Amendment”) to the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”).  The Amendment had been previously approved by the Company’s board of directors, subject to stockholder approval.

The Amendment increased the number of shares of Company common stock available for issuance under the 2010 Plan from 8,122,983 shares to 12,122,983 shares.

The 2010 Plan, as amended by the Amendment, is set forth in its entirety as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07.  Submission of Matters to a Vote of Security Holders.

On June 21, 2018, the Company held the Annual Meeting.  As of the close of business on the record date for the Annual Meeting, there were 70,039,338 shares of Company common stock issued and outstanding and entitled to vote. There were 52,014,710 shares present in person or by proxy at the Annual Meeting, constituting a quorum. The final voting results were as follows: 

Proposal 1:  Election of Directors 

Stockholders elected each of the Company’s five nominees for director, as set forth below:



 

 

 

NOMINEE

FOR

WITHHOLD

BROKER NON-VOTES

James S. Burns, D.L.S.

36,083,780

690,982

15,239,948

Veronica G.H. Jordan, Ph.D.

36,198,463

576,299

15,239,948

James T. LaFrance

36,086,780

687,982

15,239,948

Valerie B. Palmieri

36,190,313

584,449

15,239,948

David R. Schreiber

36,190,402

584,360

15,239,948



Proposal 2:  Issuance Proposal

Stockholders ratified the terms and issuance of the Company’s Series B Convertible Preferred Stock and approved the issuance of such number of shares of Company common stock issuable upon full conversion of the Series B Convertible Preferred Stock, including shares issuable pursuant to customary anti-dilution provisions, as set forth below:



 

 

 

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

36,144,944

622,846

6,972

15,239,948




 

Proposal 3:  Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

Stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 11, 2018, as set forth below:



 

 

 

 FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

36,085,515

675,072

14,175

15,239,948



Proposal 4:  Approval of the Amendment 

Stockholders approved the Amendment, as set forth below:



 

 

 

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

31,959,429

4,782,081

33,252

15,239,948



Proposal 5:  Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm

Stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018, as set forth below:





 

 

 

FOR

AGAINST

ABSTENTIONS

BROKER NON-VOTES

50,905,868

1,085,972

22,870

0



 

Item 9.01.  Financial Statements and Exhibits. 



(d)         Exhibit No.Description

10.1Vermillion Inc. Second Amended and Restated 2010 Stock Incentive Plan (as amended effective June 21, 2018)








 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







 

 



 

Vermillion, Inc.



 

 

Date: June 27, 2018

By:

/s/ Robert Beechey



 

Robert Beechey



 

Chief Financial Officer